Potential treatments for macular degeneration must go through a lengthy series of human clinical trials before seeking approval by the U.S. Food and Drug Administration.
Information about clinical trials for the United States as well as clinical trials occurring globally are available at www.clinicaltrials.gov.
Our Phase I/II clinical trials started in December 2011. Learn More.
October 1, 2012
The first grant, funded through the SBIR program with Dr. Thomas W. Chalberg as Principal Investigator, is geared toward pre-clinical development of anti-VEGF vectors for diabetic macular edema. The second grant investigates Avalanche’s delivery technology in animal models of glaucoma; this grant was funded through the STTR program and is being coordinated by Avalanche in collaboration with Cornell Weill Medical College, with Dr. Anna-Maria Demetriades as Principal Investigator... Read More
